Basic Information

Gene symbol ITGA4 Synonyms CD49D, IA4 Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas
Description integrin subunit alpha 4

GTO ID GTC0601
Trial ID ACTRN12608000226303
Disease Multiple Sclerosis
Altered gene CD49d
Therapeutic/Target gene Target gene
TherapyASO
Treatment ATL1102
PhasePhase2
Recruitment statusNot Recruiting
TitleA double-blind, placebo controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL1102 (VLA-4 antisense oligonucleotide) by subcutaneous injections in patients with multiple sclerosis.
Year2008
CountryFrance|Germany|Switzerland
Company sponsorAntisense Therapeutics Limited
Vector information
VectorNo vector was used

Clinical Result

Cohort 1
Administration route subcutaneous injection
Dosage 200 mg
Pts 72
Age Adult
Outcome ATL1102 significantly reduced the cumulative number of new active lesions by 54.4% compared to placebo (mean 3.0 [SD 6.12] vs 6.2 [9.89], p = 0.01). The cumulative number of new gadolinium-enhancing T1 lesions was reduced by 67.9% compared to placebo (p = 0.002).
Adverse reactions No serious clinical adverse events
References PMID: 25239835

Relationship Graph

Overview of Knowledge Graph